Abstract
The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 289-300 |
| Number of pages | 12 |
| Journal | Cell Stem Cell |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 3 2009 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cell Biology
- Molecular Medicine
- Genetics
Cite this
Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation. / Kiuru, Maija Ht; Boyer, Julie L.; O'Connor, Timothy P.; Crystal, Ronald G.
In: Cell Stem Cell, Vol. 4, No. 4, 03.04.2009, p. 289-300.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation
AU - Kiuru, Maija Ht
AU - Boyer, Julie L.
AU - O'Connor, Timothy P.
AU - Crystal, Ronald G.
PY - 2009/4/3
Y1 - 2009/4/3
N2 - The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
AB - The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.
UR - http://www.scopus.com/inward/record.url?scp=62949195751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62949195751&partnerID=8YFLogxK
U2 - 10.1016/j.stem.2009.03.010
DO - 10.1016/j.stem.2009.03.010
M3 - Review article
C2 - 19341619
AN - SCOPUS:62949195751
VL - 4
SP - 289
EP - 300
JO - Cell Stem Cell
JF - Cell Stem Cell
SN - 1934-5909
IS - 4
ER -